Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?
The neuroleptic malignant syndrome (NMS) of extrapyramidal signs and hyperthermia is an uncommon complication of therapy with the major tranquilizers. Other manifestations are pallor, diaphoresis, blood pressure fluctuation, tachycardia, and tachypneic hypoventilation, which may necessitate respirator support. Death often occurs, but full recovery can result with prompt recognition and proper management. In a patient with Parkinson disease and a chronic psychiatric disorder treated with haloperidol, typical features of NMS appeared upon cessation of dopaminergic antiparkinsonian drugs. Manifestations of NMS are attributed to dopamine receptor blockade in the striatum, increasing thermogenesis, and in the hypothalamus, impairing heat dissipation.
Single photon emission computed tomography with 123I-IMP in three cases of the neuroleptic malignant syndrome
Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome
Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study
Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis
The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine
Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study
Supersensitivity of d-amphetamine-induced hyperthermia in rats following continuous treatment with neuroleptics
Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome
Changes in body temperature after administration of amino acids, peptides, dopamine, neuroleptics and related agents: II
Schizophrenia, infection and temperature. An animal model for investigating their interrelationships
No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia
Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group
Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death
Fulminant metoclopramide induced neuroleptic malignant syndrome rapidly responsive to intravenous dantrolene
Rhabdomyolysis with erratic serum creatinin phosphokinase levels: intramuscular injection of haloperidol decanoate
Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease
Failure of intravascular volume expansion without hemodilution to elevate cortical blood flow in region of experimental focal ischemia
Hypervolemic hemodilution in experimental focal cerebral ischemia. Elevation of cardiac output, regional cortical blood flow, and ICP after intravascular volume expansion with low molecular weight dextran
Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome
Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification
Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam
Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment
Cyamemazine (Tercian(®)): Exploration of extrapyramidal syndrome cases contained in the French pharmacovigilance database
Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications
Atypical Neuroleptic Malignant Syndrome in the Setting of Quetiapine Overdose: A Case Report and Review of the Literature.
Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here
Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.